Hemostasis

Hemostasis

اسلاید 1: www.tabaye.ir

اسلاید 2: Hemostasis

اسلاید 3: Hemostasis („hemo”=blood; sta=„remain”) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help prevent blood loss, including:Formation of a clot

اسلاید 4: Local vasoconstrictionis due to local spasm of the smooth muscle (symp. reflex)can be maintained by platelet vasoconstrictors

اسلاید 5: Formation of platelet aggregateInjured blood vessel releases ADP, which attracts platelets (PLT)PLT comming in contact with exposed collagen release: serotonin, ADP, TXA2, which accelerate vasoconstriction and causes PLT to swell and become more sticky

اسلاید 6: The micrograph shows activated platelets adhering to some damaged cells

اسلاید 7: Formation of blood clotIn the formation of the clot, an enzyme called thrombin converts fibrinogen into insoluble protein, fibrin Fibrin aggregates to form a meshlike network at the site of vascular damage

اسلاید 8: The intrinsic system is more complex and present only in „higher” life forms (e.g. birds and reptiles possess only extrinsic system) The complex sequence of events that produce fibrin are divided into three stagesCoagulation mechanism is composed of an extrinsic and intrinsic pathway, which eventually merge into one

اسلاید 9: Extrinsic pathway:1. When blood comes in contact with injured tissue – tissue thromboplastin (F III) interacts with proconvertin (F VII), and Ca2+ activating Stuart factor (F X).Stage I: Formation of prothrombin activatorCa2+Stuart factorAnti- hemophilic factorChristmas factor

اسلاید 10: Intrinsic pathway:2. Exposed collagen activates Hageman factor (F XII). Activated F XII activates plasma enzyme – plasma thromboplastin antecedent (PTA; F XI, which in the presence of Ca 2+ activates Christmas factor (F IX). F IX interacts with antihemophilic factor (F VIII), Ca 2+ to form a complex that activates Stuart factor (F X).Stage I: Formation of prothrombin activatorCa2+Christmas factorAnti- hemophilic factorStuart factor

اسلاید 11: Stage I: Formation of prothrombin activator3. Common pathway:Activated F X in the presence of Ca 2+ forms complexes with accelerin (F V) to form prothrombin activatorCa2+Christmas factorAnti- hemophilic factorStuart factor

اسلاید 12:

اسلاید 13: Stage II: conversion of prothrombin to thrombinProthrombin – inactive precursor of enzyme thrombinIn the presence of prothrombin activator and Ca2+ prothrombin is converted to thrombinThrombin itself increases its own rate of formation (positive feedback mechanism)Ca2+

اسلاید 14: Stage III: conversion of fibrinogen to fibrinFibrinogen – plasma protein produced by the liverThrombin converts fibrinogen to fibrinThrombin also activates fibrin-stabilizing factor (F XIII), which in the presence of Ca2+, stabilizes the fibrin polymer through covalent bonding of fibrin monomersfibrin-stabilizing factor

اسلاید 15: Calcium ionsAre required for promotion and acceleration of almost all blood clotting reactionsExcept: activation of XII and XI (intrinsic mechanism)Ca2+http://www.mhhe.com/biosci/esp/2002_general/Esp/folder_structure/tr/m1/s7/trm1s7_3.htm

اسلاید 16: Ca2+Ca2+Christmas factorAnti- hemophilic factorStuart factorFibrin-stabilizing factor

اسلاید 17:

اسلاید 18: Fibrinolysis

اسلاید 19: Clot DissolutionPlasmin is formed from plasminogen - enzyme called activator (e.g. enzymes from urine, tears, saliva or bacterial enzyme streptokinase)Plasmin as an enzyme is involved in breaking down fibrin into soluble fragments (fibrinolysis) Plasminogen Plasmin Activator (e.g. t-PA)Fibrin soluble fragmentsPlasminogen may be produced by eosinophils

اسلاید 20:

اسلاید 21: AnticoagulantsHirudo medicinalis produce Hirudin that inhibits Thrombin

اسلاید 22: AnticoagulantsAlthough tissue breakdown and platelets destruction are normal events in the absence of trauma, intravascular clotting does not usually occur because:the amounts of procoagulants released are very smallnatural anticoagulants are present (Antithrombin III, Heparin, Antithromboplastin, Protein C and S, fibrin fibers)

اسلاید 23: Natural anticoagulantsAntithrombin III – inhibits factor X and thrombin Heparin from basophils and mast cells potentiates effects of antithrombin III (together they inhibit IX, X, XI, XII and thrombin)Antithromboplastin (inhibits „tissue factors” – tissue thromboplastins)Protein C and S – activated by thrombin; degrade factor Va and VIIIa

اسلاید 24: Abnormalities of hemostasis

اسلاید 25: ThrombocytopeniaSevere reduction in the number of PLTs - thrombocytopeniathis causes spontaneous bleeding as a reaction to minor traumain the skin - reddish-purple blotchy rashit may result from:decreased production (toxins, radiation, infection, leukemias)increased destruction (autoimmune processes)increased PLTs consumption (DIC)Hemorrhagic spots (petechiae)

اسلاید 26: ThrombocytopeniaLethal when PLTs<10G/LBleeding occurs when PLTs<50G/LNorm: 150-400G/L

اسلاید 27: Hepatic failureMost of the clotting factors are formed in the liverSubconjunctival hemorrhage

اسلاید 28: Disseminated intravascular coagulation (DIC)Widespread coagulation  thrombosis in small blood vessels  increased fibrinolysis, and depletion of coagulating factors  generalized bleedingIt may result from:bacterial infections (endothelial damage)disseminated cancers (release of procoagulants)complications of pregnancysevere catabolic statesDisseminated cervical cancer metastases (PET imaging)

اسلاید 29: Hemophilia A (lack of F VIII) and B (lack of F IX) are transmitted genetically and affect only males. Females carry the gen but do not show symptoms.Von Willebrand’s disease – loss of large component of fVIII

اسلاید 30: Hemophilia A (lack of F VIII; 85%)Spontaneous or traumatic subcutaneous bleedingBlood in the urineBleeding in the mouth, lips, tongueBleeding to the joints, CNS, gastrointestinal tractMild hemophilia after injection in buttock

اسلاید 31: Son of the last Tsar of Russia – Aleksy Romanow suffered from Hemophilia A

اسلاید 32: Tests of coagulation

اسلاید 33: "Intrinsic" and "extrinsic" coagulation pathwaysN: 9.9 – 13 secActivated Partial Thromboplastin TimeN: 25-35 sec Prothrombin Time

اسلاید 34: Prothrombin time (PT) test – norm 11 -15 sec evaluates extrinsic system (VII, X, V, II, fibrinogen)prolonged PT indicates a deficiency in any of factors VII, X, V, prothrombin (factor II), or fibrinogen (factor I). Prolonged PT:-   a vitamin K deficiency (vitamin K is a co-factor in the synthesis of functional factors II (prothrombin), VII, IX and X)-    liver diseaseWarfarin therapyDICexcesive heparin

اسلاید 35: International Normalised Ratio (INR)The result for the PT is expressed as a ratio (prothrombin clotting time for patient plasma divided by time for control plasma); Correction factor (International Sensitivity Index) is applied to the prothrombin ratio and the result issued as INR. Therapeutic interval: Therapeutic interval for oral anticoagulant therapy: 2.0-4.5. Application: Monitoring oral anticoagulant therapy (eg. Warfarin); note that heparin will not prolong INR (heparinase is included within the INR reagent)!!!!!!!!!!!!! For heparin therapy we monitor aPTT and/or aPTT ratio

اسلاید 36: Activated Partial Thromboplastin Time test (aPTT) – norm: 25-35 s; evaluates intrinsic system (VIII, IX, XI, XII, X, V, II, fibrinogen) an isolated prolongation of the aPTT (PT normal) suggests deficiency of factor VIII, IX, XI or XIIprolongation of both the APTT and PT suggests factor X, V, II or I (fibrinogen) deficiency, all of which are rareaPTT is normal in factor VII deficiency (PT prolonged) and factor XIII deficiencyMost common case of prolonged aPTT – heparin!!!

اسلاید 37: Thrombin time (TT) – norm: 14-15 secProlonged TT:Heparin (much more sensitive to heparin than aPTT)Hypofibrinogenemia

اسلاید 38: Selected causes of abnormal coagulation tests

اسلاید 39: "Intrinsic" and "extrinsic" coagulation pathwaysN: 9.9 – 13 secActivated Partial Thromboplastin TimeN: 25-35 sec

اسلاید 40: Whole blood clotting timeThe time taken for blood to clot mainly reflects the time required for the generation of thrombin The surface of the glass tube initiates the clotting process. This test is sensitive to the factors involved in the intrinsic pathwayThe expected range for clotting time is 4-10 mins.

اسلاید 41: Whole blood clotting time – procedure: Clean the tip of the finger with an alcohol Prick the finger tip with an automatic lancet Note the time when blood first appears on the skin Touch the tube to the drop of blood Break gently 1cm of the tube at the end of 2 min, and every 30 sec these after When fibrin is formed between the two broken pieces of tube the coagulation or clotting time is noted

اسلاید 42: Bleeding time This is a test that measures the speed in which small blood vessels close off (the condition of the blood vessels and platelet function)This test is useful for detecting bleeding tendenciesThe bleeding stops within 1 to 9 minutes. This may vary from lab to lab, depending on how the test is measuredUsing the ear lobe method, a normal bleeding time is between 1 and 4 minutes.

اسلاید 43: Bleeding time – procedure: Clean the earlobe with an alcohol Prick the earlobe with an automatic lancet Note the time when blood first appears on the skin After half a minute (30sec) place the edge of the filter paper on the top of the drop of blood.Perform the operation at half minute (30 sec) interval The end point or bleeding time is the first half minute when no blood is seen on the filter paper.

اسلاید 44: Abnormal Bleeding TimeProlonged bleeding time may indicate: A vascular (blood vessel) defect A platelet function defect (see platelet aggregation) platelets count defect (low platelets)Drugs that may increase times include dextran, indomethacin, and salicylates (including aspirin).

اسلاید 45:

اسلاید 46: The new model of haemostasis

اسلاید 47: Injury of vessels wall leads to contact between blood and subendothelial cellsFXa binds to FVa on the cell surfaceThe complex between TF and FVIIa activates FIX and FXTissue factor (TF) is exposed and binds to FVIIa or FVII whichis subsequently converted to FVIIa1. Initiation phase

اسلاید 48: The FXa/FVa complex converts small amounts of prothrombin intothrombinThe small amount of thrombin generated activates FVIII, FV, FXIand platelets locally.FXIa converts FIX to FIXa 2. Amplification phaseActivated plateletsbind FVa, FVIIIaand FIXa

اسلاید 49: The FVIIIa/FIXa complex activates FX on the surfaces of activated plateletsFXa in association with FVa converts large amounts of prothrombin into thrombin creating “thrombin burst”.3. Propagation phaseThe “thrombin burst” leads to the formation of a stable fibrin clot.

اسلاید 50: Summary: Haemostasis starts with the interaction between TF and FVIIa on the surface of subendothelial cells. The small amount of thrombin generated during the amplification phase activates platelets locally on whose surface the subsequent reactions take place. The resulting thrombin burst results in the formation of a stable clot.

اسلاید 51: NovoSeven® Mode of ActionEptacog alfa (activated)Tissue factor (TF)/FVIIa,or TF/rFVIIa interaction, is necessary to initiatiate haemostasisAt pharmacological concentrations rFVIIa directly activates FX on the surface of locally activated platelets.This activation will initiate the ”thrombin burst”independently of FVIII and FIX. This step is independent of TF.The thrombin burst leads to the formation of a stable clot

اسلاید 52: Conclusion:• In high doses rFVIIa binds to the surface of the locally activated platelets where it leads to the formation of a ”thrombin burst”

اسلاید 53: Prescribing InformationNovoSeven® Eptacog alfa (activated) Abbreviated Prescribing Information: NovoSeven [Recombinant Coagulation Factor VIIa (rFVIIa)] Presentation: Powder for injection with accompanying solvent for reconstitution (Water for Injections). Available in packs containing 1.2, 2.4 or 4.8 mg rFVIIa. Uses: Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in patients with: - congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 BU or who are expected to have a high anamnestic response to FVIII or FIX. - acquired haemophilia - congenital FVII deficiency - Glanzmann’s thrombasthenia with antibodies to GP IIb-IIIa and/or HLA, and with past or present refractoriness to platelet transfusion. Dosage: The rFVIIa is dissolved in the accompanying solvent before use. After reconstitution the solution contains 0.6 mg rFVIIa/ml. Administer by intravenous bolus injection over 2-5 minutes; must not be mixed with infusion solutions or given in a drip. Haemophilia A or B with inhibitors or acquired haemophilia Initial dose of 90g per kg body weight. Duration of, and interval between, repeat injections dependent on severity of haemorrhage or procedure/surgery performed. For mild to moderate bleeding episodes (including ambulatory treatment): 1-3 doses at 3 hour intervals (90g per kg b.w.) to achieve haemostasis, with additional dose to maintain haemostasis. Duration of ambulatory treatment should not exceed 24 hours. For serious bleeding episodes, initial dose 90g per kg. b.w.; dose every two hours until clinical improvement. If continued therapy indicated, dosage interval can be increased successively. Major bleeding episode may be treated for 2-3 weeks or longer if clinically warranted. For invasive procedures/surgery administer initial dose of 90g per kg. b.w. immediately before the procedure. Repeat dose at 2-3 hour intervals for first 24-48 hours. In major surgery continue dosing at 2-4 hour intervals for 6-7 days. Dosage interval may then be increased to 6-8 hours for further 2 weeks. Treatment may be up to 2-3 weeks until healing has occurred. Factor VII deficiency For bleeding episodes and for invasive procedures/surgery administer 15-30µg per kg b.w. every 4-6 hours until haemostasis achieved. Adapt dose and frequency to individual. Glanzmann’s thrombasthenia For bleeding episodes and for invasive procedures/surgery administer 90µg (range 80-120µg) per kg b.w. every 2 hours (1.5-2.5 hours). At least three doses should be administered to secure effective haemostasis. For patients who are not refractory platelets are first line treatment. Contra-indications: Known hypersensitivity to active substance, excipients, or to mouse, hamster or bovine protein. Precautions: For severe bleeds NovoSeven should only be administered in hospitals specialised in the treatment of patients with coagulation factor VIII or IX inhibitors or in close collaboration with a physician specialised in treatment of haemophilia. Ambulatory treatment should not exceed 24 hours. Possibility of thrombogenesis or induction of DIC in conditions in which tissue factor could be expected in circulating blood, e.g. advanced atherosclerotic disease, crush injury, septicaemia, or DIC. Since NovoSeven may contain trace amounts of mouse, bovine and hamster proteins there is a remote possibility of the development of hypersensitivity. Monitor FVII deficient patients for prothrombin time and FVII coagulant activity; suspect antibody formation if FVIIa activity fails to reach expected level or bleeding not controlled with recommended doses. Avoid simultaneous use of prothrombin complex concentrates, activated or not. Use in pregnancy: Only administer to pregnant women if clearly needed. Not known if excreted in human milk; exercise caution when administering NovoSeven to nursing women. Side Effects: Adverse reactions (serious and non-serious) reported during post-marketing period: Rare (>1/10,000, <1/1,000): Lack of efficacy. Very rare <1/10,000): Coagulopathic disorders such as increased D-dimers and consumptive coagulopathy; myocardial infarction; nausea; fever; pain, especially at injection site; increase of ALT, ALP, LDH and prothrombin levels; cerebrovascular disorders including cerebral infarction and cerebral ischaemia; skin rashes; venous thrombotic events; haemorrhage.Serious adverse reactions include: Arterial thrombotic events (such as myocardial infarction or ischaemia, cerebrovascular disorders and bowel infarction); venous thrombotic events (such as thrombophlebitis, deep vein thrombosis and pulmonary embolism). In the vast majority of cases patients were predisposed to such events. No spontaneous reports of anaphylactic reactions, but patients with a history of allergic reaction should be carefully monitored. No reports of antibodies against FVII in haemophilia A or B patients. Isolated cases of FVII-deficient patients developing antibodies against FVII reported after treatment with NovoSeven. These patients previously treated with human plasma and/or plasma derived FVII. Monitor FVII deficient patients for FVII antibodies. One case angioneurotic oedema reported in patient with Glanzmann’s thrombasthenia after administration of NovoSeven. Marketing Authorisation numbers: NovoSeven 60 KIU EU/1/96/006/001 NovoSeven 120 KIU EU/1/96/006/002 NovoSeven 240 KIU EU/1/96/006/003 Legal Category: POM Basic NHS Price: NovoSeven 1.2 mg £664.72 NovoSeven 2.4 mg £1329.44 NovoSeven 4.8 mg £2658.88 Further information: Full prescribing information can be obtained from: Novo Nordisk Limited Broadfield Park Brighton Road Crawley West Sussex RH11 9RT Tel: 01293 613555 Fax: 01293 613535 Date of preparation: May 2004 Ref N7/03/039a

اسلاید 54: A 35-year-old man complains of chronic physical fatigue, which began 3-4 weeks ago. He said he felt tired all of the time even through his occupation as a software developer was mentally but not physically demanding. He breathed comfortably at rest but, when he exerted himself, he experienced difficulty in breathing and had hard time catching his breath. He also complained of „more than usual” mental fatigue, confessing an increasing inability to concentrate and focus his attention on tasks at hands. Colleagues noticed his pallor and his inattentiveness at brainstorming sessions and suggested he reschedule his annual physical examination for an earlier date. He complained of vague abdominal pain and sense of abdominal fullness. His appetite was depressed, and he thought perhaps his physical and mental symptoms were caused by poor diet. However, attempts to increase eating resulted in nausea. His stools, he said, were sometimes loose and tarry. Eventually, increased heart palpitations and chest pain made him seek medical advice

اسلاید 55: Laboratory findings revealed the following:

اسلاید 56: Case history questions:What general medical condition is suggested by the person’s symptoms?What fundamental change in function of blood related to the red blood cells could simultaneously affect the function of several systems (cardiovascular, respiratory, gastrointestinal, and others)?What specific diagnosis is supported by the laboratory findings?How could the stool be related to the laboratory findings?

اسلاید 57: Answers:AnemiaA reduction in oxygen-carrying capacity of the blood and thus a reduction in the delivery of oxygen to various body tissuesAn iron defficiency anemiaMost cases of iron-defficiency anemia result from internal blood loss. Dark, tarry loose stools suggest bleeding from the gastrointestinal tract and warrant further tests to determine the exact cause